Form 8-K - Current report:
SEC Accession No. 0001213900-24-111528
Filing Date
2024-12-23
Accepted
2024-12-23 08:50:21
Documents
15
Period of Report
2024-12-19
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0225680-8k_optimize.htm   iXBRL 8-K 27506
2 PRESS RELEASE, DATED DECEMBER 23, 2024 ea022568001ex99-1_optimize.htm EX-99.1 10185
3 GRAPHIC ex99-1_001.jpg GRAPHIC 4361
  Complete submission text file 0001213900-24-111528.txt   222647

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE oprx-20241219.xsd EX-101.SCH 3021
5 XBRL LABEL FILE oprx-20241219_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE oprx-20241219_pre.xml EX-101.PRE 22363
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0225680-8k_optimize_htm.xml XML 3671
Mailing Address 260 CHARLES STREET SUITE 302 WALTHAM MA 02453
Business Address 260 CHARLES STREET SUITE 302 WALTHAM MA 02453 248-651-6558
OptimizeRx Corp (Filer) CIK: 0001448431 (see all company filings)

EIN.: 261265381 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38543 | Film No.: 241570219
SIC: 7389 Services-Business Services, NEC
(CF Office: 07 Trade & Services)